Zacks Research Has Optimistic Outlook of RVPH Q3 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Zacks Research lifted their Q3 2026 EPS estimates for Reviva Pharmaceuticals in a research note issued to investors on Monday, August 17th. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.40) for the quarter, up from their prior forecast of ($0.55). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($2.96) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.41) EPS and FY2028 earnings at ($0.67) EPS.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.19.

Separately, Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $75.00.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.50 on Thursday. Reviva Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $17.20. The company has a 50 day moving average price of $0.55 and a 200 day moving average price of $1.60. The stock has a market capitalization of $6.55 million, a P/E ratio of -0.27 and a beta of 0.53.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several hedge funds have recently made changes to their positions in RVPH. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals during the second quarter worth about $31,000. Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 3rd quarter valued at about $37,000. NewEdge Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 1st quarter valued at about $58,000. State Street Corp boosted its position in shares of Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.